Literature DB >> 28516329

Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.

Isabell Cordts1,2, Nicolas Bodart3, Kathi Hartmann4, Katerina Karagiorgou5,6, John S Tzartos5,6, Lin Mei7,8,9, Jens Reimann10, Philip Van Damme11,12,13, Michael H Rivner8, Alain Vigneron3, Joachim Weis2, Jörg B Schulz1,14, Socrates J Tzartos5,6, Kristl G Claeys15,16,17,18.   

Abstract

In autoimmune myasthenia gravis (MG), the identification of antibodies and characterization of serological subgroups is of great importance for diagnosis and management of the disease. Our aims were to study the frequency of antibodies against lipoprotein-related protein 4 (LRP4), agrin, and titin using the most recent techniques, and to characterize corresponding clinical features and autoimmune diseases (AID) in 100 MG-patients. The antibody frequencies in the 55 AChR-antibody positive patients were 7% LRP4, 5% agrin, 53% titin, and in the 45 AChR-antibody negative patients 2% MuSK, 2% LRP4, 2% agrin, and 27% titin. LRP4-MG presented late-onset age, mild symptoms, good therapeutic response, and no thymic changes. Agrin-MG showed early onset age, mild-to-severe symptoms, and moderate treatment response. The phenotype of titin-MG depended on AChR-antibodies: AChR-antibody negative patients presented with mostly mild limb muscle weakness, whereas AChR-antibody positive patients showed more frequently severe symptoms, including myasthenic crisis, bulbar predominance, and thymoma. Additional AID were detected in 32% of MG-patients, most frequently Hashimoto's thyroiditis (21%). Based on our data, we recommend the detection of LRP4-antibodies for at least AChR-antibody negative MG-patients and titin-antibodies for all MG-patients. We propose taking an accurate medical history for typical symptoms of Hashimoto's thyroiditis in MG-patients.

Entities:  

Keywords:  Antibodies; Autoimmune diseases; LRP4; Seronegative; Thyroid; Titin RIPA

Mesh:

Substances:

Year:  2017        PMID: 28516329     DOI: 10.1007/s00415-017-8514-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  49 in total

1.  Clinical features of patients with myasthenia gravis associated with autoimmune diseases.

Authors:  M Kanazawa; T Shimohata; K Tanaka; M Nishizawa
Journal:  Eur J Neurol       Date:  2007-10-17       Impact factor: 6.089

2.  Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study.

Authors:  Liza Gill; Allison Zarbo; Prescilia Isedeh; Gordon Jacobsen; Henry W Lim; Iltefat Hamzavi
Journal:  J Am Acad Dermatol       Date:  2015-10-27       Impact factor: 11.527

3.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.

Authors:  Reinhild Klein; Alexander Marx; Philipp Ströbel; Berthold Schalke; Wilfred Nix; Nick Willcox
Journal:  Hum Immunol       Date:  2013-06-18       Impact factor: 2.850

5.  Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease.

Authors:  C Toth; D McDonald; J Oger; K Brownell
Journal:  Acta Neurol Scand       Date:  2006-08       Impact factor: 3.209

Review 6.  Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.

Authors:  Angela Vincent; John Bowen; John Newsom-Davis; John McConville
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

Review 7.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

8.  Antititin antibody in early- and late-onset myasthenia gravis.

Authors:  P Szczudlik; B Szyluk; M Lipowska; B Ryniewicz; J Kubiszewska; M Dutkiewicz; N E Gilhus; A Kostera-Pruszczyk
Journal:  Acta Neurol Scand       Date:  2014-06-20       Impact factor: 3.209

9.  Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis.

Authors:  W R Kiessling; R Finke; P Kotulla; H Schleusener
Journal:  Acta Endocrinol (Copenh)       Date:  1982-09

10.  Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.

Authors:  Pedro M Rodríguez Cruz; Michal Al-Hajjar; Saif Huda; Leslie Jacobson; Mark Woodhall; Sandeep Jayawant; Camilla Buckley; David Hilton-Jones; David Beeson; Angela Vincent; Maria Isabel Leite; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

View more
  10 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody.

Authors:  Yuping Chen; Xiaoyong Tao; Yan Wang; Shengjie Xu; Yanhua Yang; Jinming Han; Feng Qiu
Journal:  Front Neurol       Date:  2022-05-09       Impact factor: 4.086

3.  Reduced plasmablast frequency is associated with seronegative myasthenia gravis.

Authors:  Jeffrey T Guptill; Richard Barfield; Cliburn Chan; Melissa A Russo; Doug Emmett; Shruti Raja; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; Karissa L Gable; Natalia Gonzalez; Alex Hammett; James F Howard; Manisha Chopra; Henry J Kaminski; Zaeem A Siddiqi; Mattingly Migdal; John S Yi
Journal:  Muscle Nerve       Date:  2020-12-24       Impact factor: 3.217

4.  Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Authors:  Karen Hewett; Donald B Sanders; Richard A Grove; Christine L Broderick; Todd J Rudo; Ashlyn Bassiri; Marina Zvartau-Hind; Vera Bril
Journal:  Neurology       Date:  2018-03-21       Impact factor: 9.910

5.  Late-onset Myasthenia Gravis Accompanied by Amyotrophic Lateral Sclerosis with Antibodies against the Acetylcholine Receptor and Low-density Lipoprotein Receptor-related Protein 4.

Authors:  Keiko Ohnari; Kazumasa Okada; Osamu Higuchi; Hidenori Matsuo; Hiroaki Adachi
Journal:  Intern Med       Date:  2018-10-15       Impact factor: 1.271

Review 6.  Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 7.  Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies.

Authors:  Hans Frykman; Pankaj Kumar; Joel Oger
Journal:  Front Neurol       Date:  2020-12-09       Impact factor: 4.003

Review 8.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

9.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

Review 10.  Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis.

Authors:  Zhaoming Song; Jie Zhang; Jiahao Meng; Guannan Jiang; Zeya Yan; Yanbo Yang; Zhouqing Chen; Wanchun You; Zhong Wang; Gang Chen
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.